{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:14:32Z","timestamp":1789370072540,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s11864-003-0023-x","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:38:37Z","timestamp":1183019917000},"page":"219-226","source":"Crossref","is-referenced-by-count":12,"title":["Mantle cell lymphoma: Therapeutic strategies are different from CLL"],"prefix":"10.1007","volume":"4","author":[{"given":"Wolfgang","family":"Hiddemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"23_CR1","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V76.10.2086.2086","volume":"76","author":"LJ Medeiros","year":"1990","unstructured":"Medeiros LJ, van Krieken JH, Jaffe ES, Raffeld M: Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990, 76:2086\u20132090.","journal-title":"Blood"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"9638","DOI":"10.1073\/pnas.88.21.9638","volume":"88","author":"CL Rosenberg","year":"1991","unstructured":"Rosenberg CL, Wong E, Petty EM, et al.: PRAD1, a candidate BLC1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A 1991, 88:9638\u20139642.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 10","key":"23_CR3","first-page":"93","volume":"84","author":"W Hiddemann","year":"1999","unstructured":"Hiddemann W, Dreyling M, Tiemann M, et al.: Mantle cell lymphomas. Haematologica 1999, 84(Suppl 10):93\u201395. A short and precise description of the clinical characteristics of MCL.","journal-title":"Haematologica"},{"key":"23_CR4","first-page":"115","volume":"36","author":"ES Jaffe","year":"1999","unstructured":"Jaffe ES, Campo E, Raffeld M: Mantle cell lymphoma. Semin Hematol 1999, 36:115\u2013127. An excellent histomorphologic characterization of MCL.","journal-title":"Semin Hematol"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1046\/j.1440-1827.2001.01277.x","volume":"51","author":"Y Yatabe","year":"2001","unstructured":"Yatabe Y, Suzuki R, Matsuno Y, et al.: Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int 2001, 51:747\u2013761.","journal-title":"Pathol Int"},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0016-5085(97)70212-9","volume":"112","author":"A Ruskone-Fourmestraux","year":"1997","unstructured":"Ruskone-Fourmestraux A, Delmer A, Lavergne A, et al.: Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D\u2019etude des Lymphomes Digestifs. Gastroenterology 1997, 112:7\u201316.","journal-title":"Gastroenterology"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s002770050491","volume":"78","author":"R Oinonen","year":"1999","unstructured":"Oinonen R, Franssila K, Elonen E: Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999, 78:145\u2013149.","journal-title":"Ann Hematol"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","volume":"82","author":"F Bosch","year":"1998","unstructured":"Bosch F, Lopez-Guillermo A, Campo E, et al.: Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567\u2013575.","journal-title":"Cancer"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B","volume":"64","author":"DD Weisenburger","year":"2000","unstructured":"Weisenburger DD, Vose JM, Greiner TC, et al.: Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000, 64:190\u2013196.","journal-title":"Am J Hematol"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","volume":"38","author":"NS Andersen","year":"2002","unstructured":"Andersen NS, Jensen MK, de Nully Brown P, Geisler CH: A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002, 38:401\u2013408.","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"23_CR11","first-page":"18","volume":"13","author":"M Dreyling","year":"2002","unstructured":"Dreyling M: The increasing role of prognostic factors in the choice of treatment: mantle cell lymphoma [abstract]. Ann Oncology 2002, 13(Suppl 2):18.","journal-title":"Ann Oncology"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/PL00002370","volume":"177","author":"C Frank","year":"2001","unstructured":"Frank C, Zierhut D, Schulz-Ertner D, Wannenmacher M: Centroblastic-centrocytic non-Hodgkin\u2019s lymphoma stage I-III: patterns of failure following radiotherapy. Strahlenther Onkol 2001, 177:597\u2013603.","journal-title":"Strahlenther Onkol"},{"key":"23_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","volume":"6","author":"E Zucca","year":"1995","unstructured":"Zucca E, Roggero E, Pinotti G, et al.: Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257\u2013262.","journal-title":"Ann Oncol"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hon.2900070505","volume":"7","author":"P Meusers","year":"1989","unstructured":"Meusers P, Engelhard M, Bartels H, et al.: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989, 7:365\u2013380.","journal-title":"Hematol Oncol"},{"key":"23_CR15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2000.18.4.773","volume":"18","author":"PL Zinzani","year":"2000","unstructured":"Zinzani PL, Magagnoli M, Moretti L, et al.: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle cell lymphoma. J Clin Oncol 2000, 18:773\u2013779.","journal-title":"J Clin Oncol"},{"key":"23_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","volume":"16","author":"D Decaudin","year":"1998","unstructured":"Decaudin D, Bosq J, Tertian G, et al.: Phase II trial of fludarabine monophosphate in patients with mantle cell lymphomas. J Clin Oncol 1998, 16:579\u2013583.","journal-title":"J Clin Oncol"},{"key":"23_CR17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","volume":"12","author":"H Samaha","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N, et al.: Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998, 12:1281\u20131287.","journal-title":"Leukemia"},{"key":"23_CR18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","volume":"17","author":"JM Foran","year":"1999","unstructured":"Foran JM, Rohatiner AZ, Coiffier B, et al.: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom\u2019s macroglobulinemia, and mantle cell lymphoma. J Clin Oncol 1999, 17:546\u2013553.","journal-title":"J Clin Oncol"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","volume":"38","author":"MJ Rummel","year":"2002","unstructured":"Rummel MJ, Chow KU, Karakas T, et al.: Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle cell and low grade non-Hodgkin\u2019s lymphoma. Eur J Cancer 2002, 38:1739\u20131746.","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"23_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/sonc.2003.50024","volume":"30","author":"W Hiddemann","year":"2003","unstructured":"Hiddemann W, Dreyling M, Unterhalt M: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003, 30(Suppl 2):16\u201320. This paper presents the results of the first randomized study in MCL, suggesting the benefits of combined immunochemotherapy (R-FCM).","journal-title":"Semin Oncol"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3109\/10428190109097721","volume":"42","author":"BJ Cohen","year":"2001","unstructured":"Cohen BJ, Moskowitz C, Straus D, et al.: Cyclophosphamide\/ fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42:1015\u20131022. Despite the small and inhomogenous patient population, this study confirms the efficacy of a fludarabine-containing regimen in patients with MCL.","journal-title":"Leuk Lymphoma"},{"key":"23_CR22","first-page":"302b","volume":"100","author":"M Touati","year":"2002","unstructured":"Touati M, Fitoussi O, Jaccard A, Petit B: DHAP regimen for relapsed or refractory low grade lymphomas: a study of 86 cases. Blood 2002, 100:302b.","journal-title":"Blood"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by highdose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587\u2013593. This phase II study strongly suggests the superiority of a highdose cytarabine-containing chemotherapy in comparison to a standard CHOP regimen.","journal-title":"Leukemia"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","volume":"39","author":"JE Romaguera","year":"2000","unstructured":"Romaguera JE, Khouri IF, Kantarjian HM, et al.: Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000, 39:77\u201385. The results of this dose-intensified MD Anderson (Houston, TX) approach in patients with MCL are remarkable. In addition, this alternating concept was feasible in an elderly patient cohort.","journal-title":"Leuk Lymphoma"},{"key":"23_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/cncr.10240","volume":"94","author":"JF Seymour","year":"2002","unstructured":"Seymour JF, Grigg AP, Szer J, Fox RM: Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin\u2019s lymphoma. Cancer 2002, 94:585\u2013593.","journal-title":"Cancer"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","volume":"13","author":"I Teodorovic","year":"1995","unstructured":"Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al.: Efficacy of four different regimens in 64 mantle cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin\u2019s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819\u20132826.","journal-title":"J Clin Oncol"},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"604a","DOI":"10.1182\/blood.V98.3.604","volume":"98","author":"B Coiffier","year":"2001","unstructured":"Coiffier B, Haioun C, Delaby P, et al.: Phase II study of PEG-Itron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated [abstract]. Blood 2001, 98:604a.","journal-title":"Blood"},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cncr.10663","volume":"95","author":"RM Bukowski","year":"2002","unstructured":"Bukowski RM, Tendler C, Cutler D, et al.: Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002, 95:389\u2013396.","journal-title":"Cancer"},{"key":"23_CR29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D, et al.: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317\u2013324.","journal-title":"J Clin Oncol"},{"key":"23_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1023\/A:1008301432453","volume":"11","author":"M Ghielmini","year":"2000","unstructured":"Ghielmini M, Schmitz SF, Burki K, et al.: The effect of rituximab on patients with follicular and mantle cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000, 11:123\u2013126.","journal-title":"Ann Oncol"},{"key":"23_CR31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/cbr.1997.12.177","volume":"12","author":"A Demidem","year":"1997","unstructured":"Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:176\u2013177.","journal-title":"Cancer Biother Radiopharm"},{"key":"23_CR32","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288\u20131294. This is the first full paper describing, in more detail, the effect of combined immunochemotherapy (R-CHOP) in patients with MCL. A rather short remission duration was observed.","journal-title":"J Clin Oncol"},{"key":"23_CR33","first-page":"92a","volume":"100","author":"W Hiddemann","year":"2002","unstructured":"Hiddemann W, Unterhalt M, Dreyling M, et al.: The addition of rituximab (R) to combination chemotherapy (CT) improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood 2002, 100:92a. These studies showed a superior overall survival after combined immunochemotherapy (R-FCM) in relapsed MCL.","journal-title":"Blood"},{"key":"23_CR34","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","volume":"99","author":"AK Gopal","year":"2002","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH, et al.: Highdose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158\u20133162. Although the number of patients is small, this study is a proof of principle for the radioimmunochemotherapy in the therapy-refractory entity of MCL.","journal-title":"Blood"},{"issue":"Suppl 4","key":"23_CR35","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/cncr.10307","volume":"94","author":"TM Behr","year":"2002","unstructured":"Behr TM, Griesinger F, Riggert J, et al.: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002, 94(Suppl 4):1363\u20131372.","journal-title":"Cancer"},{"key":"23_CR36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/oxfordjournals.annonc.a059156","volume":"6","author":"DA Stewart","year":"1995","unstructured":"Stewart DA, Vose JM, Weisenburger DD, et al.: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995, 6:263\u2013266.","journal-title":"Ann Oncol"},{"key":"23_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","volume":"22","author":"N Milpied","year":"1998","unstructured":"Milpied N, Gaillard F, Moreau P, et al.: High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645\u2013650.","journal-title":"Bone Marrow Transplant"},{"key":"23_CR38","first-page":"861a","volume":"98","author":"W Hiddemann","year":"2001","unstructured":"Hiddemann W, Dreyling MH, Pfreundschuh M, et al.: Myeloablative radiochemotherapy followed by autologous stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL): results of a prospective randomized European intergroup study [abstract]. Blood 2001, 98:861a. The first prospectively randomized study that confirms the benefit of an intensive consolidation concerning progressionfree survival in patients with MCL.","journal-title":"Blood"},{"key":"23_CR39","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","volume":"90","author":"NS Andersen","year":"1997","unstructured":"Andersen NS, Donovan JW, Borus JS, et al.: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212\u20134221.","journal-title":"Blood"},{"key":"23_CR40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","volume":"96","author":"M Magni","year":"2000","unstructured":"Magni M, Di Nicola M, Devizzi L, et al.: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000, 96:864\u2013869.","journal-title":"Blood"},{"key":"23_CR41","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s002770000196","volume":"79","author":"N Kroger","year":"2000","unstructured":"Kroger N, Hoffknecht M, Kruger W, et al.: Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000, 79:578\u2013580.","journal-title":"Ann Hematol"},{"key":"23_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bmt.1702567","volume":"26","author":"C Martinez","year":"2000","unstructured":"Martinez C, Carreras E, Rovira M, et al.: Patients with mantle cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 2000, 26:677\u2013679.","journal-title":"Bone Marrow Transplant"},{"key":"23_CR43","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1083-8791(01)70016-X","volume":"7","author":"JG Berdeja","year":"2001","unstructured":"Berdeja JG, Jones RJ, Zahurak ML, et al.: Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant 2001, 7:561\u2013567.","journal-title":"Biol Blood Marrow Transplant"},{"key":"23_CR44","first-page":"416a","volume":"100","author":"FI Khouri","year":"2002","unstructured":"Khouri FI, Saliba RM, Younes A, et al.: Allogeneic transplantation for poor risk mantle cell lymphoma (MCL): chemosensitivity predicts superior outcome [abstract]. Blood 2002, 100:416a.","journal-title":"Blood"},{"key":"23_CR45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/10428190290016908","volume":"43","author":"TS Lin","year":"2002","unstructured":"Lin TS, Howard OM, Neuberg DS, et al.: Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002, 43:793\u2013797.","journal-title":"Leuk Lymphoma"},{"key":"23_CR46","first-page":"465a","volume":"98","author":"L Pham","year":"2001","unstructured":"Pham L, Tamayo A, Lo P, et al.: Anti-tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells [abstract]. Blood 2001, 98:465a.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0023-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-003-0023-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0023-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0023-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T13:24:12Z","timestamp":1652621052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-003-0023-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s11864-003-0023-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}